There are few randomized controlled trials (RCTs) directly comparing subcutaneous tirzepatide with subcutaneous semaglutide
Sources New England Journal of Medicine: TripleHormone-Receptor Agonist Retatrutide for Obesity JAMA Network: FDA Issues Warnings About Compounded Versions of Semaglutide and Tirzepatide U.S
MT-1 is produced as a high-purity research material with consistent composition and verified identity, supplied in lyophilized powder format in standardized 10 mg vial packages suited for controlled handling and experimental reproducibility
For most patients starting GLP-1 treatment for weight management, semaglutide (either Wegovy or compounded) is a common first choice because it has the longest track record, the most clinical data, and the widest availability
When provided intravenously, skeletal muscle is able to use circulating NR without hepatic metabolism, but not NMN
Effectiveness: Effective for surface pigmentation but not for full-body whitening